AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...
Alcami Corporation, a contract development and manufacturing organization (CDMO), has appointed pharmaceutical industry ...
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting ...
SK pharmteco, a global contract development and manufacturing organization (CDMO), has launched an enhanced analytical testing laboratory specifically dedicated to High Potency Active Pharmaceutical ...
To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.
Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).
The project is set to become the largest GMP temperature-controlled facility fully dedicated to the life sciences sector in ...
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...
Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...
Telix Pharmaceuticals Ltd.’s prostate cancer PET imaging agent Illuccix has been approved by the Danish Medicines Agency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback